Micafungin may be safely administered as outpatient parenteral antimicrobial therapy for chronic pulmonary aspergillosis

• Published in: Mycoses 2019-02, Vol.62 (2), p.152-156
• Main Authors: Otu, Akaninyene A., Bongomin, Felix, Bazaz, Rohit, Harris, Chris, Denning, David W., Kosmidis, Chris
• Format: Article
• Language: English
• Subjects: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Ambulatory Care - methods; Antifungal Agents - administration & dosage; Antifungal Agents - adverse effects; Aspergillosis; Chronic Disease; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - pathology; Female; Humans; Intravenous administration; Male; Micafungin; Micafungin - administration & dosage; Micafungin - adverse effects; Middle Aged; Outpatients; Patients; Pulmonary Aspergillosis - drug therapy; Quality of Life; Retrospective Studies; Treatment Outcome
• ISSN: 0933-7407; 1439-0507
• DOI: 10.1111/myc.12857

Summary Background Intravenous micafungin has been reported as a treatment alternative in patients with chronic pulmonary aspergillosis (CPA) where long‐term oral triazole therapy is unfeasible. Objectives We evaluated the safety and efficacy of micafungin administered via the outpatient parenteral antimicrobial therapy (OPAT) service for the treatment of CPA. Methods We included all CPA patients who received micafungin via OPAT between April 2016 and March 2018. Data on adverse events and line‐related complications, and Quality of Life (QoL) scores at the start of micafungin course and 3 months later were extracted. Improvements in QoL were defined as an improvement of ≥4 points in at least one modality (symptom, impact, activity, total) in the St George's QoL score. A stable QoL score was defined as a change in score of